BioAtla (BCAB) Current Deferred Revenue (2020 - 2021)
BioAtla's (BCAB) quarterly Current Deferred Revenue came in at $19.8 million in Q3 2021, little changed quarter-over-quarter from $19.8 million in Q2 2021.
BioAtla (BCAB) Current Deferred Revenue (2020 - 2021) Analysis & Trends
BioAtla's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $19.8 million for Q3 2021.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $19.8 million in Q3 2021; TTM through Sep 2021 was $19.8 million, a N/A change from a year earlier, with the FY2020 full-year figure at $19.8 million, changed N/A from the prior year.
- Current Deferred Revenue held at $19.8 million in Q3 2021 per BCAB's latest filing, from $19.8 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $19.8 million in Q4 2020 and bottomed at $393000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | BioAtla | 5.08 Mn | 5.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 19.80 Mn |
| Jun 30, 2021 | 19.81 Mn |
| Mar 31, 2021 | 393,000.00 |
| Dec 31, 2020 | 19.81 Mn |